EZETIMIBE ( DrugBank: Ezetimibe )

4 diseases

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	1
79	Homozygous familial hypercholesterolemia	6
93	Primary biliary cholangitis	1
260	Sitosterolemia	11

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02548936 (ClinicalTrials.gov)	April 2015	31/8/2015	Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE	Efficacy and Safety of Simvastatin-ezetimibeCombination Therapy in Reduction of Progression of Ather ...	Atherosclerosis	Drug: Ezetimibe+Simvastatin Drug Combination	Peking Union Medical College Hospital	NULL	Enrolling by invitation	18 Years	65 Years	Both	30	Phase 0	China

First Previous1Next Last

79. Homozygous familial hypercholesterolemia

Clinical trials : 145 / Drugs : 114 - (DrugBank : 26) / Drug target genes : 8 - Drug target pathways : 17

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03933293 (ClinicalTrials.gov)	May 13, 2019	28/4/2019	A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH	A Phase 2 Study to Evaluate the Safety and Efficacy of PCSK9 Inhibitor AK102 in Patients With Homozy ...	Homozygous Familial Hypercholesterolemia	Drug: AK102;Drug: Statins;Drug: Ezetimibe	Akeso	AD Pharmaceuticals Co., Ltd.	Completed	18 Years	N/A	All	10	Phase 2	China
2	NCT03510715 (ClinicalTrials.gov)	August 31, 2018	18/4/2018	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hype ...	An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents Wi ...	Hypercholesterolemia	Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: N ...	Sanofi	Regeneron Pharmaceuticals	Completed	8 Years	17 Years	All	18	Phase 3	Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;Fra ...
3	NCT00704535 (ClinicalTrials.gov)	March 2006	23/6/2008	Evaluation of the Safety, Tolerability and Efficacy of Ezetimibeon a Select Population of Filipinos ...	Post-marketing Surveillance of the Safety, Tolerability and Efficacy of EzetimibeAmong Filipino Pati ...	Primary Hypercholesterolemia;Homozygous Familial Hypercholesterolemia	Drug: Ezetimibe	Organon and Co	NULL	Completed	18 Years	N/A	All	4105		Philippines
4	NCT00092833 (ClinicalTrials.gov)	July 2002	23/9/2004	Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653- ...	An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe10 Mg/Day to Patients With Homozyg ...	Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors	Drug: Comparator: ezetimibe	Organon and Co	NULL	Terminated	8 Years	N/A	All	49	Phase 3	United States
5	NCT03885921 (ClinicalTrials.gov)	October 25, 2000	20/3/2019	Safety and Tolerability Study of Ezetimibe(SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in H ...	Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to Atorvastatin or Sim ...	Hypercholesterolemia	Drug: Ezetimibe;Drug: Atorvastatin;Drug: Simvastatin	Organon and Co	NULL	Completed	12 Years	N/A	All	44	Phase 3	NULL
6	NCT03884452 (ClinicalTrials.gov)	May 3, 2000	6/3/2019	Ezetimibe(SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hyp ...	A Phase III Efficacy And Safety Study of Ezetimibe(SCH58235) 10 mg in Addition to Atorvastatin or Si ...	Familial Hypercholesterolemia	Drug: Atorvastatin;Drug: Simvastatin;Drug: Ezetimibe;Drug: Placebo for Ezetimibe	Organon and Co	NULL	Completed	12 Years	N/A	All	50	Phase 3	NULL

First Previous1Next Last

93. Primary biliary cholangitis

Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-006742-34-GB (EUCTR)	20/12/2007	03/06/2007	The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis.	The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis.	primary biliary cirrhosis MedDRA version: 9.1;Level: LLT;Classification code 10036680;Term: Primary ...	Trade Name: Ezetrol Product Name: Ezetimibe Product Code: EZT INN or Proposed INN: EZETIMIBE Trade Name: ...	Barts and The London NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	70	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United Kingdom

First Previous1Next Last

260. Sitosterolemia

Clinical trials : 12 / Drugs : 11 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathway : 1

diseases per page:

Showing 1 to 10 of 11 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01584206 (ClinicalTrials.gov)	April 2012	16/4/2012	Sitosterolemia Metabolism	Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe	Sitosterolemia	Drug: Ezetimibe	University of Manitoba	NULL	Completed	16 Years	99 Years	All	8	N/A	Canada
2	NCT00704444 (ClinicalTrials.gov)	June 2007	23/6/2008	A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or i ...	Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use I ...	Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia	Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s)	Organon and Co	Bayer	Completed	N/A	N/A	All	11332		NULL
3	NCT00705211 (ClinicalTrials.gov)	June 2007	23/6/2008	A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or i ...	Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long ...	Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia	Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s)	Organon and Co	Bayer	Completed	N/A	N/A	All	1794		NULL
4	EUCTR2004-001580-22-DE (EUCTR)	21/12/2004	20/10/2004	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of ...	Homozygous Sitosterolemia	Trade Name: Ezetrol Product Name: Ezetrol Product Code: MK-0653	MSD SHARP & DOHME GMBH	NULL	Not Recruiting			Female: yes Male: yes	30		Germany;United Kingdom
5	EUCTR2004-001580-22-GB (EUCTR)	16/12/2004	24/02/2005	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of ...	Homozygous Sitosterolemia	Trade Name: Ezetrol Product Name: Ezetrol Product Code: MK-0653	Merck Sharp & Dohme Ltd	NULL	Not Recruiting			Female: yes Male: yes	30		Germany;United Kingdom
6	NCT00099996 (ClinicalTrials.gov)	December 2004	21/12/2004	Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia	A Study to Assess Adding Ezetimibe30 mg to Ongoing Treatment With Ezetimibe10 mg in Patients With Ho ...	Heart Diseases;Metabolism, Inborn Errors	Drug: SCH-58235;Drug: Ezetimibe	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	N/A	N/A	Both	3	Phase 3	United States
7	NCT00092898 (ClinicalTrials.gov)	October 2004	23/9/2004	An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of ...	Lipid Metabolism, Inborn Errors;Heart Disease	Drug: MK0653, ezetimibe;Drug: Comparator: placebo	Organon and Co	NULL	Completed	18 Years	85 Years	All	30	Phase 3	United States
8	NCT00092833 (ClinicalTrials.gov)	July 2002	23/9/2004	Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653- ...	An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe10 Mg/Day to Patients With Homozyg ...	Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors	Drug: Comparator: ezetimibe	Organon and Co	NULL	Terminated	8 Years	N/A	All	49	Phase 3	United States
9	NCT00045812 (ClinicalTrials.gov)	March 2001	10/9/2002	SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygo ...	Lipoidosis	Drug: SCH-58235	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	N/A	N/A	Both	5	Phase 2	United States
10	NCT00092820 (ClinicalTrials.gov)	February 12, 2001	23/9/2004	Sitosterolemia Extension Study (0653-004)(COMPLETED)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficac ...	Lipid Metabolism, Inborn Errors;Heart Disease	Drug: MK0653, ezetimibe;Drug: Comparator: placebo	Organon and Co	NULL	Completed	10 Years	N/A	All	58	Phase 3	NULL

First Previous1 2Next Last